Kyorin Grabs Japan Negotiation Rights to Marketing Collaboration for MSD’s Cough Treatment

Kyorin Pharmaceutical signed a memorandum of understanding (MOU) with MSD for the negotiation rights for the marketing collaboration of the US giant’s investigational refractory chronic cough treatment MK-7264 in Japan, its parent Kyorin Holdings said on May 13. MK-7264 was...read more